You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Immunotherapies in Relapsed/Refractory Multiple Myeloma: 2021 Round-Up and a Look Into the Future

  • Authors: María-Victoria Mateos, MD, PhD; Faith E. Davies, MD, MRCP, MRCPath, FRCPath; Amrita Krishnan, MD, FACP; Paola Neri, MD, PhD
  • CPD Released: 2/3/2022
  • Valid for credit through: 2/3/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of hematology and oncology specialists and other members of the team outside of the United States caring for patients with multiple myeloma (MM).

The goal of this activity is to provide learners with expert perspectives on new data with immunotherapies and the potential place of novel immunotherapies in future clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical data with novel immunotherapies in patients with relapsed/refractory (R/R) MM
    • Current positioning of immunotherapies in the MM treatment paradigm
  • Demonstrate greater confidence in their ability to
    • Identify which patient with MM might be eligible for a novel non-B-cell maturation antigen (BCMA) bispecific antibody


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • María-Victoria Mateos, MD, PhD

    Professor of Medicine
    University of Salamanca
    Salamanca, Spain

    Disclosures

    Disclosure: María-Victoria Mateos, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie; Adaptive; Amgen; Bluebird; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides; Pfizer; Regeneron; Roche; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.; Takeda
    Speaker or member of speakers bureau for: Adaptive; Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides; Sanofi; Takeda

  • Faith E. Davies, MD, MRCP, MRCPath, FRCPath

    Professor of Medicine ​
    NYU Langone Health ​
    Director, Clinical Myeloma Program 
    Perlmutter Cancer Center ​
    New York, New York, United States

    Disclosures

    Disclosure:  Faith E. Davies, MD, MRCP, MRCPath, FRCPath, has the following relevant financial relationships:
    Advisor or consultant for: Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides; Sanofi; Takeda
    Speaker or member of speakers bureau for: Oncopeptides; Takeda

  • Amrita Krishnan, MD, FACP

    Director, Judy and Bernard Briskin
    Multiple Myeloma Center​
    Professor of Hematology/
    Hematopoietic Cell Transplantation​
    City of Hope Cancer Center​
    Duarte, California, United States 

    Disclosures

    Disclosure:  Amrita Krishnan, MD, FACP, has the following relevant financial relationships:
    Grants for clinical research from: Janssen
    Advisor or consultant for: Bristol Myers Squibb Company; Janssen; Pfizer; Regeneron; Sanofi; Sutro
    Speaker or member of speakers bureau for: Amgen; Bristol Myers Squibb Company; GlaxoSmithKline; Takeda
    Stocks, stock options, or bonds from: Bristol Myers Squibb Company

  • Paola Neri, MD, PhD

    Associate Professor of Medicine 
    University of Calgary 
    Calgary, Alberta, Canada

    Disclosures

    Disclosure:  Paola Neri, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Janssen; Sanofi

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships. 

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC 

    Disclosures

    Disclosure: Chii Shyang Fong, PhD, has disclosed no relevant financial relationships. 

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Immunotherapies in Relapsed/Refractory Multiple Myeloma: 2021 Round-Up and a Look Into the Future

Authors: María-Victoria Mateos, MD, PhD; Faith E. Davies, MD, MRCP, MRCPath, FRCPath; Amrita Krishnan, MD, FACP; Paola Neri, MD, PhDFaculty and Disclosures

CPD Released: 2/3/2022

Valid for credit through: 2/3/2023

processing....

Educational Impact Challenge

The goal of this activity is to provide learners with expert perspectives on new data with immunotherapies and the potential place of novel immunotherapies in future clinical practice.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print